MAP7D2 is a microtubule-stabilizing protein that functions as a critical cofactor for kinesin-1-mediated axonal transport. In the proximal axon, MAP7D2 localizes to the axon initial segment where it interacts with and promotes recruitment of kinesin-1 family members (KIF5A, KIF5B, KIF5C) to microtubules, thereby facilitating cargo entry into axons and supporting axon development and neuronal migration 1. MAP7D2 exhibits sex-specific differential expression in primate blood tissues 2, and genome-wide association analysis identified MAP7D2 variants (rs4370706) as significantly associated with age-related hearing loss in inner hair cells of the cochlea 3. In cancer biology, MAP7D2 functions as an immunosuppressive factor by interacting with MYH9 and protecting it from degradation, leading to decreased HMGB1 secretion and suppressed CD8+ T cell infiltration in microsatellite-stable colorectal cancer; MAP7D2 knockdown enhances anti-tumor immunity and improves immunotherapy efficacy 4. MAP7D2 has emerged as a prognostic marker in acute myeloid leukemia, where elevated expression correlates with worse outcomes 5, and shows gender-differential expression patterns relevant to rheumatoid arthritis pathogenesis 6. Additionally, MAP7D2 undergoes gene fusion events (MAP7D2::SND1) in pancreatic acinar cell carcinoma with potential therapeutic implications 7.